Epigenetics and Cancer Team

Aktan completed his BSc and MSc at Middle East Technical University (Ankara, Turkey). He obtained his PhD from Purdue University (Indiana, USA) in 2020 and worked as a postdoctoral fellow in CSHL until May 2023. In October 2023, Aktan joined Professor Kristian Helin’s lab at the ICR.

Sarah completed her undergraduate BSc degree in Molecular Medicine at the University of Tübingen, Germany, and Karolinska Institute, Sweden. She obtained her MSc in Molecular Medicine with a focus on Oncology from the University of Tübingen. Sarah joined Professor Kristian Helin’s lab in 2021. As a PhD student she is investigating p53 missense mutations in complex karyotype AML.

Shunlei completed his MSc in stem cell biology at the Institute of Biophysics, Chinese Academy of Sciences, where he explored the role of PTEN deficiency in transforming neural stem cells towards glioblastoma stem cells. He then obtained his PhD at University of Copenhagen, where he investigated the role of RECQL4 in maintenance of genomic stability. After obtaining his PhD, he joined Professor Kristian Helin’s lab at Biotech Research & Innovation Centre (BRIC), University of Copenhagen, where he started investigating kinases as novel therapeutic targets in AML. He continued this research in Professor Helin’s lab at the ICR since January 2022.

Zheng completed his undergraduate BSc degree in Biological Science at Fudan University, China. He then completed his Master of Biotechnology and PhD in Oncology at The University of Melbourne, Australia, where he explored the roles of cyclin-dependent kinases in regulating RNA polymerase II transcription elongation. In 2020, Zheng joined Professor Kristian Helin’s lab at the University of Copenhagen, Denmark. Since then, he has been investigating the mechanism of how Polycomb complexes repress gene expression using genome-wide CRISPR screen and single-cell sequencing technology.

Xuerui obtained her MSc in Biochemistry and Molecular Biology with a focus on structural biology from Peking University, China. After her MSc, she worked as a R&D Engineer at TransGen Biotech Co., LTD. Then she moved to Copenhagen and worked at the Center for Healthy Aging, University of Copenhagen. Xuerui joined Professor Kristian Helin’s lab in Copenhagen in 2021 and Professor Helin’s lab at ICR in 2022, where she investigated the role of DNMT3A mutation in mastocytosis.

Chang obtained his Ph.D. degree from a joint program held by the National Institute of Biological Sciences, Beijing, and the College of Biological Sciences, China Agricultural University. He worked as a research associate in the Institute of Biophysics, Chinese Academy of Science, for several years, where he characterized the biochemical regulation of the histone methyltransferase Ash1 complex. He joined Professor Kristian Helin’s team in Nov 2019. His research focuses on understanding the molecular mechanisms of leukemogenic genes and identifying novel targets for potential therapies.

Aina completed her undergraduate BSc degree in Biology from University of Barcelona, Spain. She then completed her MSc in Advanced Genetics from Autonomous University of Barcelona, Spain. In 2016, she moved to University of Navarra, Spain, to pursue her PhD in Huarte’s lab, investigating the role of non-coding RNAs in regulating genomic DNA replication, where she continued as a postdoctoral researcher for two more years. Aina joined Professor Kristian Helin’s Lab in ICR, London, in 2023, to follow her research interests in chromatin biology.

Kankadeb completed his undergraduate BSc degree in Genetics, Microbiology and Chemistry from Bangalore University, India. He completed his MSc in Molecular and Human Genetics from BHU, India. He then moved to University of Gothenburg, Sweden to pursue his research interest in epigenetics regulation mediated by long non-coding RNAs in higher organisms. After obtaining his PhD in Medicine in December 2017 and continuing postdoctoral research work for one more year in Sweden, Kankadeb joined Professor Kristian Helin’s Lab in New York in 2019. He is investigating the tissue specific role of Polycomb Repressive Complex 2 (PRC2) in DIPGs and haematological malignancies.

Van completed her undergraduate BSc degree in Biotechnology at the University of Nottingham, United Kingdom. She then obtained her MSc in Cancer biology and PhD in Clinical medicine research at Imperial College London, where she investigated the mechanism of endocrine therapy resistance and targeting transcription machinery in breast cancer. After obtaining her PhD in 2020, she continued her research as a postdoc at Imperial College London. She started in Professor Helin’s lab in 2021 where her current research focuses on unravelling the tissue specificity of PRC2 alterations in cancer.

Isabel completed her undergraduate BSc degree in Biochemistry at Complutense University of Madrid, Spain. She then completed her MSc in Molecular Biomedicine at University of Copenhagen, Denmark. In 2018, Isabel joined Professor Kristian Helin’s lab in Copenhagen to pursue her PhD, during which she explored the use of CRISPR technologies for the discovery of novel therapeutic targets for glioblastoma and acute myeloid leukemia treatment. She is continuing this research at ICR after joining in August 2022.

Hayley completed her undergraduate degree in Natural Sciences, majoring in Genetics, at Trinity College Dublin, Ireland in 2016. She then obtained her PhD in Chromatin Biology at University College London in 2021. During her PhD, she researched the molecular mechanisms by which the cohesin complex regulates chromatin organisation, with a specific focus on regulation of cohesin’s association with chromatin. In 2023, Hayley joined Professor Kristian Helin’s lab at the ICR in London. Her research focuses on the role of Polycomb Repressive Complex 2 (PRC2) in cancer and the molecular mechanism of Polycomb-mediated repression.

Tulin obtained her undergraduate BSc degree in Molecular Biology and Genetics at Bilkent University, Turkey in 2013. She completed her PhD in Stem Cell Biology at The University of Edinburgh, UK in 2018. Then, in April 2018, she moved to Denmark to join Kristian Helin’s Lab at The University of Copenhagen. She is investigating the molecular mechanism regulating tumor formation and maintenance in glioblastoma as well as the regulation of transcriptional repression by Polycomb Repressive Complexes in mouse embryonic stem cells.

Christa obtained her BSc degree at Maastricht University, the Netherlands. She then completed the Msc Oncology at the Vrije Universiteit in Amsterdam. In 2022 she started her PhD in Professor Kristian Helin’s lab where she studies p53 missense mutations in AML.